Plant Name: Fraxinus szaboana
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 5.990E-10 | 1.186E-06 | CA1, CA12, CA13, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9, MMP1, MMP2, MMP9, PTPN1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.229E-27 | 2.676E-23 | CA1, CA12, CA13, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 2.230E-06 | 2.697E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
| BP | GO:0050896; response to stimulus | GO:1901700; response to oxygen-containing compound | 9.168E-06 | 7.499E-03 | AKR1B1, CA3, CA9, CASP1, CYP1A2, HPGD, MAPK1, MMP2, MMP9, NFKB1, POLB, TSHR |
| BP | GO:0009987; cellular process | GO:0033554; cellular response to stress | 9.845E-06 | 7.499E-03 | AKR1B1, ALOX15, CA2, CA9, HIF1A, LMNA, MAPK1, MAPT, MMP9, NFKB1, POLB, PTPN1, TDP1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.317E-05 | 8.399E-03 | CA2, CA7 |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.329E-05 | 8.399E-03 | HPGD, MMP2, MMP9 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 1.350E-05 | 8.399E-03 | AKR1B1, AKR1B10, ALDH1A1, ALOX15, CYP1A2, GAA, GFER, HPGD, HSD17B10, XDH |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.317E-05 | 8.399E-03 | ADRA2A, ADRA2C |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 1.215E-05 | 8.399E-03 | AKR1B1, HIF1A, MAPK1, MAPT |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.626E-21 | 7.214E-17 | CA1, CA12, CA13, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.380E-19 | 6.010E-16 | CA1, CA12, CA13, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 7.579E-27 | 1.122E-24 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA7; CA6; CA9; CA14; CA13 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.457E-06 | 7.187E-05 | MMP1; MMP2; MAPK1; MMP9 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 4.007E-07 | 2.965E-05 | AKR1B10; GAA; HKDC1; AKR1B1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.663E-05 | 6.152E-04 | CASP7; CASP1; MAPK1; NFKB1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.471E-04 | 2.420E-03 | MMP1; MMP2; MAPK1; HIF1A; MMP9; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 5.803E-05 | 1.227E-03 | HKDC1; MAPK1; HIF1A; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 7.499E-05 | 1.387E-03 | CASP7; MAPK1; MMP9; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.905E-04 | 2.621E-03 | CASP7; LMNA; MAPK1; NFKB1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 3.806E-05 | 1.007E-03 | AKR1B10; HKDC1; AKR1B1 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 1.948E-04 | 2.621E-03 | CASP7; CASP1; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 3.818E-04 | 4.036E-03 | CASP7; MAPK1; MAPT; HSD17B10 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 7.532E-04 | 6.771E-03 | AKR1B10; GAA; HKDC1; CYP1A2; ALOX15; ALDH1A1; AKR1B1; HSD17B10; XDH |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 3.497E-04 | 3.981E-03 | HKDC1; MAPK1; HIF1A |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 2.167E-04 | 2.672E-03 | CASP1; MAPK1; NFKB1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 7.777E-04 | 6.771E-03 | MMP2; MAPK1; HIF1A; MMP9 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.159E-03 | 9.029E-03 | MMP2; MAPK1; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.094E-03 | 8.996E-03 | MMP2; MAPK1; MMP9 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 7.272E-04 | 6.771E-03 | CASP1; MAPK1; NFKB1 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 2.437E-03 | 1.663E-02 | NMUR2; ADRA2C; ADRA2A; TSHR |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 3.316E-03 | 2.045E-02 | MAPK1; MMP9; NFKB1 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 2.887E-03 | 1.858E-02 | PTPN1; HKDC1; MAPK1 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 4.830E-03 | 2.749E-02 | MAPK1; ADRA2C; ADRA2A |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 5.500E-03 | 3.006E-02 | CASP1; MAPK1; NFKB1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 5.946E-03 | 3.006E-02 | HPGD; MMP9; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 7.834E-03 | 3.153E-02 | MAPK1; NFKB1; TSHR |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 8.496E-03 | 3.224E-02 | POLB; MAPK1; NFKB1 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 4.357E-03 | 2.579E-02 | HKDC1; MAPK1 |
| hsa00500 | Starch and sucrose metabolism_Homo sapiens_hsa00500 | 5.887E-03 | 3.006E-02 | GAA; HKDC1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 6.094E-03 | 3.006E-02 | MAPK1; NFKB1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 6.732E-03 | 3.113E-02 | MAPK1; HIF1A |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 6.516E-03 | 3.111E-02 | AKR1B10; AKR1B1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.529E-02 | 4.713E-02 | MAPK1; MAPT; NFKB1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 2.472E-03 | 1.663E-02 | AKR1B10; AKR1B1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.607E-03 | 1.189E-02 | CYP1A2; ALOX15 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 8.095E-03 | 3.153E-02 | MAPK1; NFKB1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 9.572E-03 | 3.358E-02 | MAPK1; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 8.095E-03 | 3.153E-02 | MAPK1; HIF1A |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 9.829E-03 | 3.358E-02 | MAPK1; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 9.829E-03 | 3.358E-02 | MAPK1; NFKB1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 4.084E-05 | 1.007E-03 | CYP1A2; XDH |
| hsa04623 | Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | 7.628E-03 | 3.153E-02 | CASP1; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 7.860E-03 | 3.153E-02 | CYP1A2; ALDH1A1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.435E-02 | 4.616E-02 | MAPK1; NFKB1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.496E-02 | 4.712E-02 | MMP2; MAPK1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 7.860E-03 | 3.153E-02 | MAPK1; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 9.829E-03 | 3.358E-02 | MAPK1; NFKB1 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.009E-02 | 3.358E-02 | PTPN1; MAPK1 |
| hsa00524 | Butirosin and neomycin biosynthesis_Homo sapiens_hsa00524 | 1.021E-02 | 3.358E-02 | HKDC1 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA2C; ADRA2A; ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; NFKB1 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; ADRA2C |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1; MMP1; AKR1B1 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; MAPK1; CA1; CA9; MMP9; NFKB1; MMP2; ACHE |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; MAPK1; CA9; MMP9; MMP2 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1; ADRA2C; ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ADRA2C; ACHE; ACHE; ACHE; MAPT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C; ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2 |